| Protein | Synonyms | Taxonomy |
|---|
| Polyunsaturated fatty acid 5-lipoxygenase | EC 1.13.11.-; Arachidonate 5-lipoxygenase; 5-LO; 5-lipoxygenase; 1.13.11.34 | Homo sapiens (human) |
| Prostaglandin G/H synthase 2 | EC 1.14.99.1; Cyclooxygenase-2; COX-2; PHS II; Prostaglandin H2 synthase 2; PGH synthase 2; PGHS-2; Prostaglandin-endoperoxide synthase 2 | Homo sapiens (human) |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | 12/15-lipoxygenase; Arachidonate 12-lipoxygenase, leukocyte-type; 12-LOX; 1.13.11.31; Arachidonate 15-lipoxygenase; 15-LOX; 15-LOX-1; 1.13.11.33; Arachidonate omega-6 lipoxygenase; Hepoxilin A3 synthase Alox15; 1.13.11.-; Linoleate 13S-lipoxygenase; 1.13. | Homo sapiens (human) |
| Acyl-CoA (8-3)-desaturase | EC 1.14.19.44; Delta(5) fatty acid desaturase; D5D; Delta(5) desaturase; Delta-5 desaturase; Fatty acid desaturase 1 | Homo sapiens (human) |
| Acyl-CoA 6-desaturase | EC 1.14.19.3; Delta(6) fatty acid desaturase; D6D; Delta(6) desaturase; Delta-6 desaturase; Fatty acid desaturase 2 | Homo sapiens (human) |
| Polyunsaturated fatty acid lipoxygenase ALOX12 | EC 1.13.11.-; Arachidonate (12S)-lipoxygenase; 12S-LOX; 12S-lipoxygenase; 1.13.11.31; Arachidonate (15S)-lipoxygenase; 1.13.11.33; Linoleate (13S)-lipoxygenase; Lipoxin synthase 12-LO; 3.3.2.-; Platelet-type lipoxygenase 12 | Homo sapiens (human) |
| Compound | Description |
|---|
| linoleic acid | A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed) |
| gamma-linolenic acid | An omega-6 fatty acid produced in the body as the delta 6-desaturase metabolite of linoleic acid. It is converted to dihomo-gamma-linolenic acid, a biosynthetic precursor of monoenoic prostaglandins such as PGE1. (From Merck Index, 11th ed) |
| alpha-linolenic acid | A fatty acid that is found in plants and involved in the formation of prostaglandins. |
| 5-hydroxy-6,8,11,14-eicosatetraenoic acid | |
| 12-hydroxy-5,8,10,14,17-eicospentaenoic acid | RN given refers to cpd without isomeric designation |
| arachidonic acid | An unsaturated, essential fatty acid. It is found in animal and human fat as well as in the liver, brain, and glandular organs, and is a constituent of animal phosphatides. It is formed by the synthesis from dietary linoleic acid and is a precursor in the biosynthesis of prostaglandins, thromboxanes, and leukotrienes. |
| prostaglandin h2 | A cyclic endoperoxide intermediate produced by the action of CYCLOOXYGENASE on ARACHIDONIC ACID. It is further converted by a series of specific enzymes to the series 2 prostaglandins. |
| leukotriene a4 | (2S-(2 alpha,3 beta(1E,3E,5Z,8Z)))-3-(1,3,5,8-Tetradecatetraenyl)oxiranebutanoic acid. An unstable allylic epoxide, formed from the immediate precursor 5-HPETE via the stereospecific removal of a proton at C-10 and dehydration. Its biological actions are determined primarily by its metabolites, i.e., LEUKOTRIENE B4 and cysteinyl-leukotrienes. Alternatively, leukotriene A4 is converted into LEUKOTRIENE C4 by glutathione-S-transferase or into 5,6-di-HETE by the epoxide-hydrolase. (From Dictionary of Prostaglandins and Related Compounds, 1990) |
| prostaglandin g2 | |
| lipoxin B4 | structure in first source |
| 15-hydroxy-5,8,11,13-eicosatetraenoic acid | potent & selective inhibitor of platelet lipoxygenase; RN given refers to cpd without isomeric designation |
| arachidonic acid 5-hydroperoxide | 5-HPETE is used inconsistently in literature as syn for cpds with various tetraene locants; RN given refers to (6,8,11,14)-isomer; RN in CA Vol 91 Form Index for (E,Z,Z,Z)-isomer: 70968-82-0; RN for (5,8,11,13)-isomer: 71133-12-5; in Merck, arachidonic acid is the (5,8,11,14)-isomer |
| 12-hydroxy-5,8,10,14-eicosatetraenoic acid | A lipoxygenase metabolite of ARACHIDONIC ACID. It is a highly selective ligand used to label mu-opioid receptors in both membranes and tissue sections. The 12-S-HETE analog has been reported to augment tumor cell metastatic potential through activation of protein kinase C. (J Pharmacol Exp Ther 1995; 274(3):1545-51; J Natl Cancer Inst 1994; 86(15):1145-51) |